Camurus supports two Global Awareness Days for rare diseases
In November Camurus is supporting two awareness days for rare diseases – the World Acromegaly Day on 1 November and the World NET Cancer Day on 10 November.
With the support and collaboration with advocacy organizations in charge, Camurus wants to raise awareness and connect with the company’s commitment of improving the lives of patients with severe and chronic diseases.
About World Acromegaly Day
The World Acromegaly Day, which takes place annually on 1 November, aims to raise awareness for patients diagnosed with acromegaly. The campaign is organized by WAPO - The World Alliance of Pituitary Organization, with the goal to shorten time to diagnosis and improve access to appropriate care.1
Acromegaly is a hormonal disorder most often caused by a tumor in the pituitary gland, which results in an overproduction of growth hormone. Symptoms may include gradual changes in visual appearance, such as enlarged hands, feet and altered facial features, as well as enlargement of internal organs, headache, impaired vision, joint pain, sleep disturbance and reproductive disorders. If left untreated, acromegaly can be life-limiting.
About World NET Cancer Day
The World NET Cancer Day takes place on 10 November and is coordinated and organized by the International Neuroendocrine Cancer Alliance (INCA). The aim of the campaign is to increase knowledge and raise awareness of the signs and symptoms of Neuroendocrine Tumors (NETs) to encourage earlier diagnosis.2
NET is the umbrella term for a group of cancers that start in neuroendocrine cells. The tumors can arise throughout the body, though most commonly in the gastrointestinal tract and lungs. Often, a person has no symptoms until the tumor spreads, making a timely diagnosis challenging. The incidence of NET is still on the rise and symptom awareness is key to earlier diagnoses and appropriate care.
Learn more about acromegaly and NET on www.camurus.com/disease-areas/
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.